The inhibitory activity of Tregs, through cell–cell contact with immune cells occurs mainly via the co-inhibitory receptors, including CTLA4 [57] and PD1 [58], which have been targeted clinically to improve anti-tumor T-cell responses [10]. This evidence concerns the gene CTLA4 and neoplasm.